BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia

Go back to BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia

BeyondSpring (BYSI) to Resume Trading at 8:30 a.m.

December 1, 2021 8:17 AM EST

BeyondSpring (NASDAQ: BYSI) to Resume Trading at 8:30 a.m.

... More